血清cripto-1作为肺癌的临床标志物。

Serum cripto-1 as a clinical marker for lung cancer.

作者信息

Xu Chun-Hua, Cao Lan, Wei Ying, Yu Li-Ke

机构信息

Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu - PR China.

Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu - PR China.

出版信息

Int J Biol Markers. 2015 Nov 11;30(4):e369-73. doi: 10.5301/jbm.5000155.

DOI:10.5301/jbm.5000155

PMID:26109366

Abstract

BACKGROUND

Cripto-1 (CR-1) plays an important role in angiogenesis related to tumor growth, in concert with vascular endothelial growth factor (VEGF), and enhanced expression of CR-1 has been reported in lung cancer tissue.

METHODS

Patients with lung cancer (n = 156) and healthy volunteers (n = 60) were enrolled in the study. Serum CR-1 and VEGF concentrations were measured using enzyme-linked immunosorbent assay.

RESULTS

Patients with lung cancer had higher serum CR-1 (4.03 ± 1.49 ng/mL vs. 1.13 ± 0.43 ng/mL, p<0.05) and VEGF (503.62 ± 112.74 pg/mL vs. 398.62 ± 117.84 pg/mL, p<0.05) levels than the control group. With stage progression in non-small cell lung cancer (NSCLC), serum CR-1 levels increased, and patients with distant metastasis had higher levels than those without metastasis (p<0.05). In NSCLC, the low CR-1 group (<1.54 ng/mL) had a better overall survival rate compared with the high CR-1 group (>1.54 ng/mL, p<0.05).

CONCLUSIONS

Our study suggests that serum CR-1 is a useful diagnostic and prognostic marker for NSCLC patients.

摘要

背景

Cripto-1（CR-1）与血管内皮生长因子（VEGF）协同作用，在肿瘤生长相关的血管生成中发挥重要作用，且已有报道称肺癌组织中CR-1表达增强。

方法

本研究纳入了156例肺癌患者和60例健康志愿者。采用酶联免疫吸附测定法检测血清CR-1和VEGF浓度。

结果

肺癌患者血清CR-1（4.03±1.49 ng/mL对1.13±0.43 ng/mL，p<0.05）和VEGF（503.62±112.74 pg/mL对398.62±117.84 pg/mL，p<0.05）水平高于对照组。在非小细胞肺癌（NSCLC）中，随着分期进展，血清CR-1水平升高，远处转移患者的水平高于无转移患者（p<0.05）。在NSCLC中，低CR-1组（<1.54 ng/mL）的总生存率高于高CR-1组（>1.54 ng/mL，p<0.05）。